Lafayette Investments, Inc. Lineage Cell Therapeutics, Inc. Transaction History
Lafayette Investments, Inc.
- $437 Million
- Q2 2024
A detailed history of Lafayette Investments, Inc. transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Lafayette Investments, Inc. holds 13,000 shares of LCTX stock, worth $11,830. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,000
Previous 13,000
-0.0%
Holding current value
$11,830
Previous $19,000
31.58%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding LCTX
# of Institutions
122Shares Held
94.4MCall Options Held
31.3KPut Options Held
400-
Broadwood Capital Inc New York, NY41.7MShares$37.9 Million3.19% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$8.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.47MShares$7.71 Million0.0% of portfolio
-
Defender Capital, Llc.4.97MShares$4.53 Million1.77% of portfolio
-
Logos Global Management LP San Francisco, CA4.7MShares$4.28 Million0.44% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $154M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...